HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing in Brief: Prescriptives

This article was originally published in The Rose Sheet

Executive Summary

Prescriptives: Uplift Firming Eye Cream "help[s] diminish the appearance of fine lines and wrinkles" with natural polymers and "optical enhancing ingredients," Prescriptives said. Enzyme inhibitors "help impede the damaging breakdown of elastin and collagen," while Novaspheres deliver moisture to the skin, according to the Estee Lauder division. The eye cream also contains wheat protein to "help firm the eye area" and hyaluronic acid to "bind water to skin cells," Prescriptives said. The plant extract centella asiatica "supports collagen and elastin synthesis for long-term firming," the company added. The eye cream is a follow-up to Prescriptive's Uplift Active Firming cream, which debuted in October 1995. On-counter in December, a .5 oz. eye cream will be priced at $35...

You may also be interested in...



Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal

Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel